XtalPi reports record growth, first H1 profit

XtalPi reported H1 2025 revenue of RMB 517 million, up 404% YoY, and adjusted net profit of RMB 141 million, its first half-year profit. Revenue growth was driven by a 615% surge in drug discovery solutions, milestone collaborations such as a USD 51 million deal with professor Gregory Verdine, and advances in AI- and robotics-enabled R&D platforms.